{"transactions":[{"id":1974386,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:31:17.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":63338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."}],"balance_after":63338,"derivative":{"exercise_price":32.07,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":63338},"source":{"system":"sec-edgar","filing":"0000899243-23-006984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006984/doc4.xml","form_type":"4"}},{"id":1974385,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:31:17.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":164,"price":31.3973,"value":5149.1572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18986,"source":{"system":"sec-edgar","filing":"0000899243-23-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006984/doc4.xml","form_type":"4"}},{"id":1974384,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:31:17.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":550,"price":30.8774,"value":16982.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19150,"source":{"system":"sec-edgar","filing":"0000899243-23-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006984/doc4.xml","form_type":"4"}},{"id":1974383,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:31:17.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":10557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the \"ESPP\") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022."}],"balance_after":19700,"source":{"system":"sec-edgar","filing":"0000899243-23-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006984/doc4.xml","form_type":"4"}},{"id":2355174,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:30:21.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date."}],"balance_after":41000,"derivative":{"exercise_price":38.53,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000899243-22-009074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322009074/doc4.xml","form_type":"4"}},{"id":2355173,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:30:21.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0000899243-22-009074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322009074/doc4.xml","form_type":"4"}},{"id":2661466,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":116035,"kind":"person","name":"Caughey Elaine","position":1,"cik":"0001868668","reported_name":"Caughey Elaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T21:36:39.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option shall vest on June 21, 2022, and the remainder shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":47.56,"expiration_date":"2031-06-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-025048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321025048/doc4.xml","form_type":"4"}}]}